Omeros Corporation will be presenting new research revealing the clinical utility of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preventing inflammation and intraoperative pupil constriction at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting to be held in May 1-5 in Seattle, Washington and at the American Socienty of Cataract and Refractive Surgery (ASCRS) Congress in May 6-10 in New Orleans, Louisiana.
Omeros is committed to the development and commercialization of both orphan indications targeting disorders of the central nervous system, coagulopathies and inflammation as well as protein/small-molecule therapeutics for large markets. Omero’s OMIDRIA® is the only FDA-approved product that can be used during intraocular lens replacement or cataract surgery to maintain pupil size and to reduce postoperative ocular pain. It is also the only FDA-approved product containing NSAIDs that can be used intraocularly.
“As utilization of OMIDRIA in cataract surgery continues to grow, we are accumulating a wealth of data across varied ophthalmic conditions, clinical settings and practice patterns,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros in a press release.
At the ARVO 2016 Annual Meeting, a poster entitled “A comparison of the frequency of use of the Malyugin ring with & without intracameral phenylephrine & ketorolac 1% / 0.3% (phenyl/keto) injection at the time of routine cataract surgery” will be presented by Dr. Bucci.
At the ASCRS Congress, Omeros’ researchers will be giving five oral presentations showing their data on OMIDRIA use and the complications associated with intraoperative pupil dilation (miosis). The presentations, titled “Rates of complications associated with intraoperative miosis during cataract surgery in the U.S.” “Use of iris fixation ring with and without intracameral phenylephrine/ketorolac in patients with poor pupil dilation,” “Initial experience, visual outcomes, and efficacy of intracameral phenylephrine and ketorolac (1.0% / 0.3%) during cataract surgery,” Effect of phenylpephrine/ketorolac in maintaining mydriasis and intraoperative and first 24-hour comfort level during routine cataract surgery,” and “Intracameral phenylpherine/ketorolac to maintain pupil diameter and reduce postoperative pain regardless of cataract surgery duration” will be presented May 8-9 at the New Orleans Ernest N. Memorial Convention Center.
“These findings underscore the important benefits of OMIDRIA to both patients and surgeons – improving outcomes, streamlining procedures and reducing risks,” said Gregory Demopulos.
The post Recent Studies With Omeros’ OMIDRIA To Be Presented at Upcoming Ophthalmology Conferences appeared first on Cataract News Today.